A medical textile product includes a textile substrate having opposed first and second surfaces with the textile substrate including a textile construction of one or more yarns. The second surface includes a coating of a substantially water-insoluble, non-porous elastomeric sealant. The one or more yarns at the first surface are pre-treated with a removable composition, such that the water-insoluble elastomeric sealant encapsulates a portion of fibers of the one or more yarns at the second surface of the textile substrate. The textile substrate is substantially impermeable to fluid. The first surface is substantially free of the substantially water-insoluble elastomeric sealant. The textile substrate may be a non-tubular substrate, such as a planar sheet, a shaped sheet, and a tape, or a tubular substrate, such as a cylindrical conduit, a tubular conduit, a Y-shaped, a T-shaped conduit, a multi-channel conduit, and a bulbous shaped conduit.

The present invention relates to a method for preparing a chitosan matrix having good mechanical properties comprising the steps of a) preparing a solution of chitosan, b) pouring the solution of a) into a mould in order to form a layer, c) lyophilizing the layer of b) in order to obtain a matrix of chitosan, d) sterilizing the matrix obtained in c) by water vapor treatment. The invention also relates to the matrices obtained and to surgical implants comprising such matrices. The invention further relates to a method for increasing the suture retention strength of a chitosan matrix obtained by lyophilization of a chitosan solution, and to a method for for decreasing the solubilization rate in hydrochloric acid of a chitosan matrix obtained by lyophilization of a chitosan solution, comprising the step of sterilizing said matrix by a water vapor treatment.

The present invention provides a means effective for bone regeneration or bone augmentation.

Provided is a method of bone regeneration or bone augmentation, comprising: implanting a porous composite at a site in need of the bone regeneration or bone augmentation, and administering parathyroid hormone (PTH) to a subject in need of the bone regeneration or bone augmentation, wherein the porous composite comprises calcium phosphate.

Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGFβ inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.

A medical appliance or prosthesis may comprise one or more layers of rotational spun nanofibers, including rotational spun polymers. The rotational spun material may comprise layers including layers of polytetrafluoroethylene (PTFE). Rotational spun nanofiber mats of certain porosities may permit tissue ingrowth into or attachment to the prosthesis. Additionally, one or more cuffs may be configured to allow tissue ingrowth to anchor the prosthesis.

A medical appliance or prosthesis may comprise one or more layers of electrospun nanofibers, including electrospun polymers. The electrospun material may comprise layers including layers of polytetrafluoroethylene (PTFE). Electrospun nanofiber mats of certain porosities may permit tissue ingrowth into or attachment to the prosthesis.

The present disclosure relates generally to materials and medical devices impregnated with antimicrobial compounds. More specifically, the materials are medical matrix materials comprising nanopores or nanochannels in which the antimicrobial compounds are disposed. In other embodiments, medical matrix materials comprises nanomaterials and antimicrobials distributed throughout the material. The materials described herein are useful for a broad spectrum of medical devices and consumer products. The present disclosure further provides methods of making the antimicrobial materials and medical devices disclosed herein.

A medical implant is provided that has a first and a second electrospun component with the same type of biodegradable electrospun polymers. In one example, the second electrospun component is separately manufactured from the first electrospun component. Furthermore, the implant is structured such that the first electrospun component and the second electrospun component are assembled or joint together by the same type biodegradable electrospun polymers as in the first electrospun component and the second electrospun component. The assembled implant is a porous, biodegradable medical implant capable of being replaced by naturally ingrown tissue over time upon implantation. Advantages are the avoidance of sutures and the problems associated with the use of sutures, capability of ETR, avoidance of the need for extra materials, allowance for more precise and reproducible assembled structures for which the process could be automated.

The invention is an improved biocompatible surface for a variety of medical purposes. The biocompatible surface employs a unique tight microstructure that demonstrates enhanced cellular response in the body, particularly when placed in contact with blood. As a blood contact surface, the present invention can be beneficially employed in a wide variety of implantable devices and in many other devices and equipment that come in contact with blood.

An implantable bioreactor containing a barrier which is designed to allow the release of cell-derived biomolecules, but restricts the entry of immunologic and other cells, or the egress of the cells contained within the bioreactor. Two broad classes of implantable bioreactors are envisioned, encompassing devices for both systemic delivery of the bio-products and local delivery at the target tissue. Bioreactors of both classes can be implanted via surgery, through percutaneous techniques, or other techniques which effect implantation.